| 51 |
27318273 | Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease. | 2016 Oct |
1 |
| 52 |
27729794 | Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study. | 2016 |
1 |
| 53 |
28635937 | [A role of the MAO-B inhibitor rasagiline in treatment of Parkinson's disease]. | 2016 |
3 |
| 54 |
25368372 | Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia. | 2015 Jul |
1 |
| 55 |
25420207 | Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. | 2015 Jan |
1 |
| 56 |
25514361 | Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein. | 2015 Feb 18 |
1 |
| 57 |
25863936 | Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection. | 2015 Oct |
1 |
| 58 |
26364897 | Rasagiline for the treatment of Parkinson's disease: an update. | 2015 |
2 |
| 59 |
24055209 | Rasagiline induced hypersexuality in Parkinson's disease. | 2014 Mar |
1 |
| 60 |
24447649 | Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study. | 2014 Mar |
2 |
| 61 |
24769350 | Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents. | 2014 Jun 10 |
1 |
| 62 |
25196265 | Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease. | 2014 Oct |
2 |
| 63 |
25314256 | Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). | 2014 Dec |
1 |
| 64 |
25322951 | Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. | 2014 Nov |
4 |
| 65 |
26000219 | Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature. | 2014 Jun |
1 |
| 66 |
22968599 | Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. | 2013 Mar |
1 |
| 67 |
23176073 | Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. | 2013 Jan |
1 |
| 68 |
23242744 | In silico identification of novel and selective monoamine oxidase B inhibitors. | 2013 Jun |
1 |
| 69 |
23410161 | Rationally designed multi-targeted agents against neurodegenerative diseases. | 2013 |
2 |
| 70 |
23410524 | An update on amine oxidase inhibitors: multifaceted drugs. | 2013 Jul 1 |
1 |
| 71 |
23634791 | Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease. | 2013 Jul |
7 |
| 72 |
23735235 | Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. | 2013 Aug |
2 |
| 73 |
24012376 | Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B). | 2013 Nov 1 |
2 |
| 74 |
24190245 | Effects of rasagiline on olfactory function in patients with Parkinson’s disease. | 2013 Dec |
1 |
| 75 |
21628600 | The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? | 2012 May |
7 |
| 76 |
21819487 | Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. | 2012 Feb |
1 |
| 77 |
22065207 | Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. | 2012 Apr |
2 |
| 78 |
22436387 | Synthesis and evaluation of [¹⁸F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). | 2012 May 1 |
3 |
| 79 |
22439669 | Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. | 2012 Mar 26 |
2 |
| 80 |
22691758 | Therapies in Parkinson's disease. | 2012 Aug |
1 |
| 81 |
22954444 | Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro. | 2012 Nov 15 |
2 |
| 82 |
23030609 | QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: computer-aided generation of new rasagiline bioisosteres. | 2012 |
3 |
| 83 |
23231395 | Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. | 2012 |
1 |
| 84 |
23346517 | Successful use of rasagiline in combination with two antidepressants: a case report. | 2012 Nov |
2 |
| 85 |
21075154 | Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. | 2011 Jan |
1 |
| 86 |
21360301 | Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. | 2011 Mar |
1 |
| 87 |
21423589 | Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. | 2011 Jan 20 |
2 |
| 88 |
21500280 | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. | 2011 Aug 15 |
2 |
| 89 |
21626552 | Milestones in Parkinson's disease therapeutics. | 2011 May |
1 |
| 90 |
21812497 | Disease modification in Parkinson's disease. | 2011 Aug 1 |
1 |
| 91 |
21939547 | Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. | 2011 Sep 22 |
1 |
| 92 |
21947069 | [The role of the MAO-B inhibitor razagiline in the treatment of Parkinson's disease]. | 2011 |
1 |
| 93 |
21953831 | Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. | 2011 Nov |
3 |
| 94 |
21971006 | Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. | 2011 |
1 |
| 95 |
21971007 | Rasagiline in Parkinson's disease. | 2011 |
1 |
| 96 |
22045282 | Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment. | 2011 Nov |
1 |
| 97 |
22087552 | Advanced strategies for treatment of Parkinson's disease: the role of early treatment. | 2011 Oct |
1 |
| 98 |
22110357 | MAO-inhibitors in Parkinson's Disease. | 2011 Mar |
1 |
| 99 |
22133327 | Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. | 2011 Dec 1 |
1 |
| 100 |
20002521 | The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. | 2010 Mar |
3 |